Chemical Information
Antiviral agent ID	DrugRepV_4623
Antiviral agent name	Infergen
Common Name	Interferon alfacon-1
Synonyms	IFN Alfacon-1 |IFN-Con1 | Interferon alfacon-1
Structural Information
2-D Structure is not available	3-D Structure is not available
Clinical Information
Category	Anticancer
Primary Indication (Clinical trial phases)	Approved, Investigational
Biological Information
Primary Indication (Disease Category)	Non Infectious Disease
Primary Indication (Disease)	Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcom
Secondary Indication	Severe acute respiratory syndrome coronavirus (SARS-CoV) NA Urbani
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Model system) [cell lines/ animal models]	Vero76
Secondary Indication (Mode of viral infection)	Adsorption
Secondary Indication (Viral titer)	<0.007 CCID50 per cell
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Time of drug delivery)	During infection
Secondary Indication (Duration of drug delivery)	3 days
Secondary Indication (Drug concentration)	>0.32 μg/ml
Secondary Indication (Cell based assay)	Cytopathic effect (CPE) assay
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	IC50 [ 50 % ]
Reference	Day CW, Baric R, Cai SX, Frieman M, Kumaki Y, Morrey JD, Smee DF, Barnard DL..A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo..Virology. 2009 Dec 20;395(2):210-22. doi: 10.1016/j.virol.2009.09.023. Epub 2009 Oct 22. PubMed Cent PMID:19853271
Comment	In v2163-infected mice, AmpligenTM was fully protective, stinging nettle lectin (UDA) was partially protective, ribavirin was disputable and possibly exacerbated disease, and EP128533 was inactive. Ribavirin, UDA, and AmpligenTM decreased IL-6 expression.